| Literature DB >> 34133657 |
Geisa Nascimento de Andrade1, Iracema Ioco Kikuchi Umeda2, Angela Rubia Cavalcanti Neves Fuchs2, Luiz Eduardo Mastrocola2, João Manoel Rossi-Neto2, Dalmo Antonio Ribeiro Moreira2, Patricia Alves de Oliveira3, Carmen Diva Saldiva de André4, Lawrence Patrick Cahalin5, Naomi Kondo Nakagawa1.
Abstract
OBJECTIVES: We aimed to compare the effects of home-and center-based exercise training programs on functional capacity, inspiratory muscle strength, daily physical activity level, and quality of life (QoL) in patients with chronic heart failure (CHF) over a 12-week period.Entities:
Mesh:
Year: 2021 PMID: 34133657 PMCID: PMC8158670 DOI: 10.6061/clinics/2021/e2550
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Figure 1Study design of interventions and assessments. CPX, cardiopulmonary test; HR, heart rate; 1RM, one repetition maximum; MIP, maximal inspiratory pressure; QoL, quality of life.
Figure 2Recruitment and intervention flowchart. HF, heart failure; LVEF, left ventricular ejection fraction; PASP, pulmonary artery systolic pressure.
Demographic and clinical characteristics of home-based and center-based groups.
| Home-based (n=11) | Center-based (n=12) |
| |
|---|---|---|---|
|
| 59±5 | 61±7 | 0.733 |
|
| 5 (46) | 9 (75) | 0.147 |
|
| 28±4 | 27±3 | 0.460 |
|
| 31±6 | 32±6 | 0.711 |
|
| 10 (91) | 11 (92) | 0.949 |
|
| 11±8 | 9±9 | 0.557 |
|
| 0.278 | ||
| Ischemic | 2 (18) | 6 (50) | 0.265 |
| Dilated | 6 (55) | 4 (33) | 0.265 |
|
| 0.339 | ||
| Sinus rhythm | 8 (73) | 8 (67) | 0.752 |
| Atrial fibrillation | 0 (0) | 2 (17) | 0.156 |
| Implantable cardiac device | 3 (27) | 2 (17) | 0.538 |
|
| |||
| Hypertension | 10 (91) | 10 (83) | 0.590 |
| Diabetes | 3 (27) | 3 (25) | 0.901 |
| Dyslipidemia | 8 (73) | 7 (58) | 0.469 |
| Myocardial infarction | 4 (36) | 6 (50) | 0.510 |
|
| 0.265 | ||
| Never smoker, n (%) | 2 (18) | 6 (50) | 0.110 |
| Ex-smoker, n (%) | 8 (73) | 5 (42) | 0.133 |
| Current smoker, n (%) | 1 (9) | 1 (8) | 0.949 |
| Mean pack-years | 15±16 | 11±17 | 0.187 |
|
| |||
| Amiodarone | 4 (36) | 4 (33) | 0.879 |
| Diuretics | 10 (91) | 9 (75) | 0.315 |
| Spironolactone | 6 (55) | 7 (58) | 0.855 |
| Beta blockers | 11 (100) | 12 (100) | 0.999 |
| Angiotensin-converting enzyme inhibitors | 7 (64) | 9 (65) | 0.554 |
| Angiotensin II receptor blockers | 3 (27) | 1 (8) | 0.231 |
| Digoxin | 1 (9) | 0 (0) | 0.286 |
| Anticoagulants | 1 (9) | 1 (8) | 0.949 |
| Antiplatelets | 8 (73) | 9 (75) | 0.901 |
| Statins | 6 (55) | 10 (83) | 0.134 |
Continuous data: Mann-Whitney test; categorical data: chi-squared test BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional classification.
Functional capacity, physical activity level, and quality of life (mean values±SD) at baseline and after 12 weeks in both groups using a mixed linear model and physical activity level assessed by the IPAQ, using a non-parametric two-way analysis of variance for repeated measures.
| Home-based n=11 | Centre-based n=12 |
|
|
| |||
|---|---|---|---|---|---|---|---|
| Baseline | 12 weeks | Baseline | 12 weeks | ||||
|
| |||||||
| Exercise time (s) | 579±144 | 645±119 | 567±148 | 645±90 | 0.872 | 0.842 | 0.059 |
| Peak heart rate (bpm) | 117±13 | 122±18 | 116±22 | 123±26 | 0.848 | 0.985 | 0.268 |
| Peak VO2 (mL/kg/min) | 19.2±3.9 | 20.0±4.2 | 19.5±5.3 | 23.2±6.1 | 0.085 | 0.448 | 0.011* |
| AT VO2 (mL/kg/min) | 13.3±2.7 | 13.5±3.7 | 12.9±2.9 | 14.5±3.7 | 0.367 | 0.920 | 0.235 |
| VE/VCO2 slope | 31.6±6.4 | 33.4±5.8 | 31.4±8.0 | 30.7±8.1 | 0.196 | 0.594 | 0.657 |
| Maximal ventilation (L/min) | 51.4±15.2 | 62.9±28.2 | 58.8±30.6 | 74.4±33.7 | 0.775 | 0.429 | 0.015** |
| Oxygen pulse | 12.1±2.7 | 12.1±3.1 | 13.6±3.9 | 15.2±4.0 | 0.108 | 0.129 | 0.130 |
| Peak respiratory exchange ratio | 1.1±0.1 | 1.1±0.1 | 1.1±0.2 | 1.1±0.1 | 0.868 | 0.852 | 0.781 |
|
| 460.7±63.7 | 500.7±86.1 | 513.1±77.1 | 538.6±72.3 | 0.805 | 0.013 | 0.002£ |
|
| |||||||
|
| |||||||
| Sedentary, n (%) | 1 (10) | 0 (0) | 5 (42) | 0 (10) | 0.299 | 0.428 | 0.001 |
| Irregularly active, n (%) | 5 (45) | 1 (10) | 3 (25) | 0 (10) | |||
| Active, n (%) | 5 (45) | 10 (90) | 4 (33) | 12 (100) | |||
|
| |||||||
| Number of steps per day | 7335±015 | 6873±2819 | 5640±2259 | 6541±2225 | 0.001α,β | 0.258 | 0.832 |
| Number of sedentary bouts per day | 18.5±8.5 | 17.1±6.7 | 23.9±5.8 | 22.4±6.9 | 0.972 | 0.062 | 0.214 |
| Sedentary bouts length (mins/bout) | 19.7±10.0 | 18.1±7.8 | 26.3±7.3 | 23.0±7.7 | 0.472 | 0.092 | 0.050 |
| Sedentary time (mins/day) | 539±133 | 526±111 | 625±86 | 587±140 | 0.581 | 0.113 | 0.266 |
| Time spent on light activities (mins/day) | 360±118 | 333±104 | 299±87 | 323±90 | 0.080 | 0.382 | 0.931 |
| Time spent on moderate-vigorous activities (mins/day) | 23±16 | 23±9 | 13±9 | 21±16 | 0.199 | 0.218 | 0.190 |
|
| |||||||
| MLHF | 29±33 | 28±33 | 35±24 | 22±13 | 0.039# | 0.965 | 0.023 |
| SF-36 - Mental Health | 73±32 | 68±33 | 61±23 | 72±16 | 0.001## | 0.848 | 0.342 |
AT, anaerobic threshold; IPAQ, International Physical Activity Questionnaire; MLHF, Minnesota Living with Heart Failure Questionnaire; SF-36, Short-Form 36 questionnaire; VCO2, volume of exhaled carbon dioxide; VE, expiratory minute volume; VO2, oxygen uptake; 6 MW, 6-min walk test. *Mean difference=2.2 (95% CI: 0.5-3.9); **Mean difference=12.9 (95% CI: 2.6-23.2); £ Mean difference=32.4 (95% CI: 16.5-48.4); αHome-based vs centre-based at baseline: p=0.001, Mean difference=2103 (95% CI: 1229-2977); βCentre-based at baseline vs 12 weeks: p=0.031, Mean difference=901 (95% CI: 67-1735); #Centre-based at baseline vs 12 weeks: p=0.014, Mean difference=13.2 (95% CI: 2.3-24.1); ##p=0.031 Home-based vs centre-based at baseline and p=0.037 Centre-based at baseline vs 12 weeks, using Tukey multiple comparison procedure.
Figure 3Respiratory and peripheral muscle strength at baseline and at 4, 8, 12 weeks of training. #vs baseline, p=0.019 using Tukey’s multiple comparison test.